2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
5
Active not recruiting
3
Terminated
2
Recruiting
1
Sponsor Class
OTHER
1
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
1
Non Castrate Metastatic Prostate Cancer
1
Interventions
Cyclophosphamide
390
Carboplatin
344
Gemcitabine
332
pembrolizumab
329
Cisplatin
328
Paclitaxel
297
Radiotherapy
296
Docetaxel
286
Bevacizumab
253
Rituximab
234
Capecitabine
223
Nivolumab
220
Dexamethasone
206
Fluorouracil
190
fludarabine
177
Oxaliplatin
177
Pemetrexed
153
Doxorubicin
153
Irinotecan
148
Leucovorin
144
Etoposide
144
Cytarabine
133
Cetuximab
129
Bortezomib
129
fludarabine phosphate
128
Lenalidomide
126
Erlotinib Hydrochloride
120
Filgrastim
119
Temozolomide
113
Radiosurgery
113
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Buserelin
×
Clear all
NCT00651326
2023-08-04
DART
Canadian Cancer Trials Group
Phase 3
Terminated
48 enrolled
NCT02487823
2017-11-17
NCMPC-BKM
Institut Paoli-Calmettes
Phase 1
Terminated
6 enrolled